Abstract
Lanadelumab, a kallikrein inhibitor, was approved for prophylactic treatment of hereditary angioedema (HAE) in 2018. The HAE-subtype characterized by normal C1 esterase inhibitor levels (NC1-INH-HAE) is highly burdensome and complex to treat. This chart review reports the real-world effectiveness of lanadelumab in patients with NC1-INH-HAE.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
